Advertisement

PentaVision

Optometric Management

Article

LEADING OFF: Also Notable

Optometric Management April 1, 2023 Vol 58, Issue April 2023 Page(s): 17
  • Alcon launched its new Alcon Experience Academy (AEA) app to help improve the digital learning experiences of eye care professionals. The AEA app offers courses of varying levels in 17 languages as well as newly launched podcasts and discussion forums on relevant eye care topics. It can be downloaded via the Apple App Store or Google Play. More information is available at AlconExperienceAcademy.com .
  • BioTissue completed an expansion and renovation of its manufacturing and distribution facility in Doral, Fla., including a new cleanroom space and the renovation of 9,000 square feet to align with the U.S. Food and Drug Administration’s (FDA’s) Current Good Manufacturing Practice regulations. The renovation prepares BioTissue for its upcoming FDA Biologics License Application process and increases the company’s product manufacturing capacity to keep up with current and expected future demand.
  • At Vision Expo East, the Contact Lens Institute shared insights into new research that shows a significant number of vision corrected U.S. adults are interested in purchasing both contact lenses and glasses, representing a largely untapped “dual wear” growth opportunity. In its survey of more than 2,000 Americans, the CLI found that while only about one in four (23.6%) adults reported using both contact lenses and glasses, there’s considerable interest in dual wear among the remaining population. Almost one in five glasses-only wearers are very interested in contact lenses (18%), and the same percentage of contact lens-only wearers are very interested in glasses. An extensive report on the research will be published this month, according to a CLI news release.
  • EssilorLuxottica renewed its licensing agreement with Target Corp., serving guests in 2,000 stores and at Target.com, for the operation and management of Target Optical. The multi-year agreement became effective on Feb. 12; Target Optical provides comprehensive eye care services for more than 1.4 million guests, according to the press release.
  • Leaders of the International Agency for the Prevention of Blindness (IABP) discussed with the leadership of the World Health Organization the global call for a United Nations Special Envoy on Vision. More than 60 U.N. member states have signed a letter encouraging the U.N. Secretary-General to appoint a Special Envoy of the Secretary-General on Vision to serve as a global champion for vision and eye health.
  • Levation Pharma received FDA clearance to initiate a Phase I/II of LEV102 for the treatment of Acquired Blepharoptosis in adults. LEV102 is a colorless, odorless, rapidly drying gel that contains oxymetazoline as the active pharmaceutical ingredient. Oxymetazoline is an alpha-adrenergic agonist that is intended to activate the receptors on Mueller’s muscle in the upper lid. The product is designed to function as a primer and be compatible with commercially available eye shadows.
  • Myopia Profile launched Myopia Management with Spectacles, a two-hour online course designed that covers all aspects of spectacle lens prescribing for myopia, from first corrections in very young children to progressive addition and bifocal lenses through the latest technologies and next generation lenses for myopia control. For more information, go to bit.ly/MyopiaManagementWithSpectacles .
  • The Neuro-Optometric Rehabilitation Association is offering up to 10 students and residents with an interest in neuro-rehabilitation an opportunity to apply for a student grant to attend the organization’s 2023 Annual Conference (October 5-8, 2023) at the Portland Marriott Downtown Waterfront in Portland, Ore. Each grant recipient will receive full conference registration and $500 in travel grant funds; submissions must be made by June 30. More details at bit.ly/NORAconferencegrants2023 .
  • Notal Vision presented data at the Angiogenesis, Exudation, and Degeneration and Macula Society 2023 meetings on the latest data collected from its investigational home-based optical coherence tomography (OCT). The presentation reviewed several clinical trials – in which more than 200 subjects and more than 8 retina specialists participated – that show the progress toward implementing homeOCT in the management of patients with wet AMD.
  • NovaBay Pharmaceuticals began a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Avenova.com and through Avenova’s physician-dispensed channel. Organic Tears is a lubricant eye drop with no additives or artificial chemicals and is certified by the USDA as 100% organic and preservative-free.
  • Orasis Pharmaceuticals announced that the FDA has accepted for review the company’s New Drug Application (NDA) for its investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%) for the treatment of presbyopia. The FDA assigned a Prescription Drug User Fee Act goal date of October 22, 2023. The NDA is based on data from the Phase 3 NEAR-1 and NEAR-2 clinical trials, which evaluated the efficacy and safety of CSF-1.
  • Regeneron Pharmaceuticals announced the FDA accepted a Biologics License Application for aflibercept 8 mg for treatment of patients with wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The FDA target action date is June 27, following the use of a priority review voucher.
  • Transitions Optical announced that its Transitions Academy 2023 will occur from May 21 to May 24, 2023, at the JW Marriott Grande Lakes, in Orlando, Fla. The event will provide industry professionals with presentations, guest speakers, and Transitions product and professional development workshops, according to the press release. Additionally, the winners of the 2022 Transitions Innovation Awards will be announced during the event. Industry professionals interested in learning more about Transitions Academy 2023 can visit TransitionsAcademy.com .

What to Read Next